Synchronous primary gastric diffuse large B-cell lymphoma and multiple lung primary adenocarcinoma with pulmonary cryptococosis: a case report and literature review

doi:10.21203/rs.3.rs-3728906/v1

Download PDF

Case Report

Synchronous primary gastric diffuse large B-cell lymphoma and multiple lung primary adenocarcinoma with pulmonary cryptococosis: a case report and literature review

https://doi.org/10.21203/rs.3.rs-3728906/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 24 Oct, 2024

Read the published version in BMC Pulmonary Medicine →

You are reading this latest preprint version

Background

The coexistence of non-Hodgkin’s lymphoma of the stomach and multiple primary lung adenocarcinomas with pulmonary cryptococcosis has rarely been reported.

Case presentation:

We herein present a 75-year-old man who was admitted to our hospital due to hematemesis. Gastroscopy and imaging revealed extensive stomach wall thickening and multiple lung lesions, including nodules and cavernous lesion. The patient was diagnosed with primary diffuse large B-cell lymphoma via gastroscopy and bilateral lung primary adenocarcinoma with cryptococcal infection via percutaneous CT-guided puncture biopsy. He subsequently underwent six cycles of R-CHOP regimen for gastric lymphoma, along with CT-guided radiofrequency ablation for bilateral primary lung adenocarcinoma, supplemented with antifungal therapy. After a definite diagnosis and systemic treatment, the patient was followed up for twenty-seven months with no tumor recurrence, progression or metastasis.

Conclusion

To the best of our knowledge, this is the first report of the complex combination of multiple primary malignancies and pulmonary cryptococcal infection. The diagnosis is been confusing and challenging. CT-guided needle biopsy can help achieve pathological diagnosis, elucidate the type and stage of the tumor, and even change the clinical treatment strategy, which is necessary and beneficial.

pulmonary cryptococcosis

stomach

non-Hodgkin’s lymphoma (NHL)

lung

adenocarcinoma

The metachronous occurrence of other malignancies such as lung cancer in patients with non-Hodgkin’s lymphoma (NHL) during the clinical course is not necessary rare^[1]. However, the coexistence of two primary malignancies, gastric NHL and lung adenocarcinoma, has rarely been reported. We herein present an extremely rare case of coincidental primary diffuse large B-cell gastric lymphoma, bilateral primary lung adenocarcinoma, and pulmonary cryptococcosis in an immunocompetent patient. To the best of our knowledge, this is the first case report of such coexistence.

A 75-year-old Chinese man was admitted to our hospital in June 2021 due to hematemesis. He did not have fever, nocturnal diaphoresis, or significant weight loss exceeding 10% within the preceding six months. The results of his physical examination were unremarkable. The patient had no history of smoking or malignancy. His abnormal laboratory findings on admission included hemoglobin level of 6.2 g/dL and positive occult blood in the feces. Leukocyte count and lymphocyte percentage were normal. He also tested negative for human immunodeficiency virus (HIV). Gastroscopy revealed a huge lesion, approximately 6 × 7 cm, with an irregular margin at the gastric body on the next day (Fig. 1A). Endoscopic biopsy revealed diffuse large B-cell lymphoma (DLBCL) (Fig. 1B). The diagnosis was further confirmed by immunohistochemistry; positive stains for CD20, CD45, CD79a, and bcl-6; and negative stains for CD3, CD10, and CK (pan). To further evaluate the extent of gastric lymphoma-surrounding invasion, contrast-enhanced CT scan of the whole abdomen was performed, and extensive gastric wall thickening with mild homogeneous enhancement was observed (Fig. 1C, 1D). Routine chest CT examination on admission revealed different types of nodule and cavitary lesion in the lungs, which would first be considered for metastatic disease, adding significantly to the diagnostic challenge in this case. Axial CT images showed a nodule measuring 1.5 × 1.5cm in the upper lobe of the right lung (Fig. 2A), a ground-glass opacity (GGO) measuring 1 cm in the lower lobe of the left lung, and a cave-in lesion measuring 2.5 × 2.3 cm in the dorsal segment of the left lower lobe near the left oblique fissure (Fig. 2B, 2C). No significantly enlarged lymph nodes were observed in the mediastinum or bilateral hilum. As the three lesions with different imaging manifestations revealed, it was difficult to distinguish between metastatic tumors, primary lung tumors, tuberculosis, and other diseases in an elderly man who has just been diagnosed with gastric malignant tumor. CT-guided biopsies of the three lesions were separately performed. Lung nodule and GGO lesions were primary lung adenocarcinoma, the expression of EGFR positive (Fig. 2D) with positive mutation for EGFR (exon 21 L858R mutation). The cavitary lesion was proven to be Cryptococcus gattii infection (Fig. 2E). To correct staging, fluorine 18-labeled fluorodeoxyglucose-positron emission tomography-CT (PET-CT) and bone marrow biopsy were performed. PET-CT revealed an abnormal uptake in the gastric lesion and three lung lesions (Fig. 3A, 3B, 3C), whereas bone marrow biopsy was normal. Therefore, the patient was diagnosed with synchronous primary DLBCL, bilateral primary lung adenocarcinoma, and pulmonary cryptococcosis.

According to the patient’s condition and own choice, an individualized treatment plan was made after comprehensive consideration. First, CT-guided radiofrequency ablation (RFA) of the right lung adenocarcinoma was performed. Three days later, ten radioactive particles were implanted into the left lung adenocarcinoma. Because the lesion was so close to the descending aorta, not suitable for using RFA therapy. The patient’s postintervention course was uneventful, and the patient underwent six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen. Furthermore, before and during chemotherapy, the patient was administered fluconazole for pulmonary cryptococcosis. As the lung adenocarcinoma was positive for EGFR mutation, gefitinib was recommended, but the patient declined due to financial reasons. If lung adenocarcinoma progresses and deteriorates in the future, molecular targeted drugs can be used as an alternative treatment. After a definite diagnosis and systemic treatment, the patient was followed up for twenty-seven months with no tumor recurrence, progression or metastasis.

The gastrointestinal tract is the most common extranodal site affected by NHL, accounting for about 50–60% of all extranodal cases^[2], whereas the stomach is the most common gastrointestinal site (60–75%)^[3]. Patients with NHL have a higher rate of secondary malignancy than the general population, and lung cancer is the most common type^{[4, 5]}, chemotherapy such as CHOP or CHOP-like regimen and radiotherapy should be accounted for it^{[1, 6, 7]}. However, coexistence of primary lymphoma and primary lung cancer has rarely been reported. After an extensive literature search, only eleven other published cases were identified ^[8–18] (Table 1).

Table 1

Synchronous malignant lymphoma and lung cancer in the literature
Year/^ref.	Age /gender	Lung cancer	Malignant lymphoma	Treatment	Outcome	Survival time (months)
1999/^[8]	71/F	SCC	TCL/lung	lobectomy + chemotherapy(CHOP)	died of progression of lymphoma	7
2000/^[9]	67/M	SCC	MALToma/lung	lobectomy + chemotherapy (THP-COP)	died of pulmonary fibrosis due to chemotherapy	11
2001/^[10]	74/M	Adenoca	MALToma/lung	lobectomy	alive	12
2002/^[11]	67/M	SCC	MALToma/lung	lobectomy + chemotherapy (CHOP + carboplastin plus taxol)	alive	6
2008/^[12]	73/M	Adenoca	MCL/pleura	chemotherapy Endoxan + Farmorubicin + Vincristine)	alive	14
2008/^[13]	74/M	Adenoca	MALToma/lung	lobectomy, NHL was left untreated	N/A	N/A
2012/^[14]	60/F	Adenoca	MALToma/lung	lobectomy, NHL was left untreated	N/A	N/A
2017/^[15]	45/M	Adenoca	MCL/lung	6 cures of alternating RCHOP and RDHAP (dexamethasone, high-dose Ara-Cytarabine and cisplatin) + autologous stem cell transplantation.	died of treatment complications	36
2020/^[16]	69/F	Adenoca	MALToma/lung	lobectomy + chemotherapy (CHOP)	alive	12
2020/^[17]	64/M	SCC	MALToma/lung	N/A	N/A	N/A
2021/^{(The current case)}	75/M	Adenoca	DLBCL/stomach	RFA + chemotherapy(R-CHOP) + Radioactive seed implantation	alive	27
2023/^[18]	63/M	SCC	MALToma/lung	surgical resection	alive	N/A
SCC: squamous cell carcinoma; Adenoca: Adenocarcinoma; TCL: T-cell lymphoma; MALToma: Mucosa-associated lymphoid tissue lymphoma; MCL: Mantle cell lymphoma; DLBCL: diffuse large B-cell lymphoma; THP-COP: cyclophosphamide, pirarubicin, vincristine, and prednisolone;

As presented in Table 1, all the twelve cases, including our case, were older than 45 years with a mean age of 66.8 years, and nine of them were men. All these cases suffered from non-small-cell lung cancer (NSCLC), and the most common type of lymphoma was mucosa-associated lymphoid tissue type (eight cases). The present case could be the first case of synchronous gastric lymphoma and lung cancer. Although the exact etiology of synchronous gastric lymphoma and lung cancer remains unknown, some scholars speculated that common predisposing factors, including smoking, Helicobacter pylori (H. pylori) infection, and genomic alternations, may play a role^{[9, 10, 13]}. For the present case, however, the patient never smoked and was negative for H. pylori infection. In addition, the patient’s chromosome karyotype was normal, and no gene mutations other than EGFR were identified. Thus, whether the two primary malignancies observed in the present case were correlated or whether they were the result of independent events could not be confirmed.

Reviewing the eleven reported cases, the treatment protocols varied from observation to surgery, chemotherapy or in combination; however, the best treatment option remains controversial. Therefore, an individualized management is necessary. The present case is an old man who could not tolerate two entirely different types of chemotherapy, whereas R-CHOP regimen is the best choice for NHL; thus, the two lung cancer lesions were locally treated and managed first. CT-guided RFA was selected as it is an effective and minimally invasive treatment for medically inoperable NSCLC^[19]. However, the left lung adenocarcinoma was not suitable for RFA; therefore, radioactive particle implantation was opted instead. Another key point to consider is prophylactic antifungal treatment before and during chemotherapy as the mortality of disseminated cryptococcosis after the R-CHOP regimen has been reported to be as high as 54%^{[20, 21]}. After undergoing a series of treatment, the patient was finally discharged from our hospital with complete remission of gastric lymphoma and stable remission of lung adenocarcinoma; pulmonary cryptococcosis was also successfully treated.

In conclusion, synchronous primary diffuse large B-cell gastric lymphoma and bilateral primary lung adenocarcinoma is extremely rare, with the present case being the only one reported. This case highlights the need for proper staging and investigation of questionable findings before developing a patient’s treatment plan. The good clinical condition of the patient and CT scan results during the clinical follow-up indicated that the treatment was successful; however, the most suitable treatment protocol still needs to be identified on a case-by-case basis.

CT: computed tomography;

HIV: human immunodeficiency virus;

NSCLC: non-small-cell lung cancer;

NHL: non-Hodgkin’s lymphoma;

DLBCL: diffuse large B-cell lymphoma;

GGO: ground-glass opacity;

RFA: radiofrequency ablation;

FDG: fluorodeoxyglucose;

PET-CT: positron emission tomography-CT;

SCC: squamous cell carcinoma;

TCL: T-cell lymphoma;

MALToma: mucosa-associated lymphoid tissue lymphoma;

MCL: mantle cell lymphoma

Acknowledgments

The authors wish to thank the Intervention Department team of the Second Affiliated Hospital of Zhejiang University for their help and collaborations.

Authors’ contributions

KLY, LW Conception or design of the study and drafting of the manuscript; KLY, KJ, JJW acquisition of the data; KLY, ZQY, KJ, LW critical revision of the manuscript for important intellectual content, LW final approval of the version to be submitted; All authors read and approved the final manuscript.

Funding

This study was supported by Health Science and Technology Program of Shaoxing City (No. 2022KY070)

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. KLY, KJ, and LW will make the data available to readers.

Ethics approval and consent to participate

The studies involving human participants were reviewed and approved by the ethics committee of the Affiliated Hospital of Shaoxing University. All methods were performed in accordance with the relevant guidelines and regulations. Informed consents were acquired from all study individuals for the acquisition of clinical and pathological information and the use of clinical specimens.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103(4):1222–8.
Tseng C-E, Shu T-W, Lin C-W, Liao K-S. Synchronous adenocarcinoma and extranodal natural killer/T-cell lymphoma of the colon: A case report and literature review. World J gastroenterology: WJG. 2013;19(11):1850–4.
Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T. Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006;47(10):2140–6.
Brennan P, Coates M, Armstrong B, Colin D, Boffetta P. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales. Australia Br J cancer. 2000;82(7):1344–7.
Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF. Second cancers following non-Hodgkin's lymphoma. Cancer. 1991;67(7):2002–9.
Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol. 2006;24(10):1568–74.
Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica. 2006;91(11):1481–8.
Kawashima O, Sakata S, Kamiyoshihara M, Maeshima A, Ishikawa S, Morishita Y. Primary pulmonary collision tumor including squamous cell carcinoma and T-cell lymphoma. Lung Cancer. 1999;23(1):67–70.
Suzuki T, Akizawa T, Suzuki H, Kitazume K, Omine M, Mitsuya T. Primary tracheal mucosa-associated lymphoid tissue lymphoma accompanying lung Cancer. Japanese J Thorac Cardiovasc Surg. 2000;48(12):817–9.
Chanel S, Burke L, Fiche M, Molina T, Lerochais JP, Icard P, Diebold J, Galateau-Sallé F. Synchronous pulmonary adenocarcinoma and extranodal marginal zone/low-grade B-cell lymphoma of MALT type. Hum Pathol. 2001;32(1):129–32.
Rothenburger M, Semik M, Hoffmeier A, Baba H, Kamanabrou D, Roos N, Schmidt C, Scheld H. Coexistence of non-Hodgkin's lymphoma and non-small-cell lung carcinoma: diagnosis and treatment. Thorac Cardiovasc Surg. 2002;50(01):59–61.
Hatzibougias D, Bobos M, Karayannopoulou G, Karkavelas G, Karapanagiotidis GT, Foroulis CN, Kostopoulos I. A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World J Surg Oncol. 2008;6(1):137.
Ichihara E, Tabata M, Takigawa N, Sato Y, Kondo E, Aoe M, Kiura K, Tanimoto M. Synchronous pulmonary MALT lymphoma and pulmonary adenocarcinoma after metachronous gastric MALT lymphoma and gastric adenocarcinoma. J Thorac Oncol. 2008;3(11):1362–3.
Jung CY, Kwon KY. A Case of Synchronous Lung Adenocarcinoma and Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type. Tuberc Respir Dis. 2012;73(1):61–6.
Braham E, Zarrouk M, Mlika M, Kilani T, El Mezni F. Synchronous mantle cell lymph node lymphoma and pulmonary adenocarcinoma: a case report with literature review. Clin Respir J. 2017;11(4):430–2.
Sun L, Zhang B, Xuan K, Qi L, Wang J, Li Q, Liu J, Wang Y, Sun L, Li X, Ji H. Synchronous primary pulmonary adenocarcinoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: A case report and literature review. Med (Baltim). 2020;99(29):e20865.
Zhang CS, Yang XR, Ding W, Lu XY, Shen L, Zhao YF. Pulmonary mucosa-associated lymphoid tissue lymphoma concurrent with lung squamous cell carcinoma: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(12):1071–1076.Chinese.
Guo Z, Hu L, Chen Q, Hu J, Liu J, Hu W. Synchronous pulmonary MALT lymphoma and squamous cell lung cancer: a case report. World J Surg Oncol. 2023;21(1):182.
Morris DL. A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol. 2008;15(6):1765–74.
Yao K, Qiu X, Hu H, Han Y, Zhang W, Xia R, Wang L, Fang J. Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: a case report and literature review. BMC Pulm Med. 2020;20(1):161.
Hirai Y, Ainoda Y, Shoji T, Fujita T, Yoshinaga K, Shiseki M, Mori N, Teramura M, Totsuka K, Motoji T. Disseminated cryptococcosis in a non-Hodgkin’s lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. Mycopathologia. 2011;172(3):227–32.

No competing interests reported.

Download PDF

Journal Publication

published 24 Oct, 2024

Read the published version in BMC Pulmonary Medicine →

Editorial decision: Revision requested
02 Jul, 2024
Reviews received at journal
01 Jul, 2024
Reviewers agreed at journal
30 Jun, 2024
Reviewers agreed at journal
28 Jun, 2024
Reviewers agreed at journal
26 Jun, 2024
Reviews received at journal
20 Jun, 2024
Reviewers agreed at journal
20 Jun, 2024
Reviewers invited by journal
22 Mar, 2024
Editor assigned by journal
21 Mar, 2024
Editor invited by journal
28 Dec, 2023
Submission checks completed at journal
28 Dec, 2023
First submitted to journal
09 Dec, 2023

You are reading this latest preprint version

Synchronous primary gastric diffuse large B-cell lymphoma and multiple lung primary adenocarcinoma with pulmonary cryptococosis: a case report and literature review

Status:

Journal Publication

Version 1

Abstract

Background

Case presentation:

Conclusion

Figures

Background

Case presentation

Discussion and conclusions

Abbreviations

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1